# US 2022/0267276 A1 · Nlrp modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0267276 A1
- Document ID: US20220267276A1
- Status: Published application
- Kind: A1
- Application number: 17/252,623
- Filed: 2019-07-02
- Published: 2022-08-25
- Earliest claimed: 2018-07-03
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Luigi FRANCHI; Shomir GHOSH; Gary GLICK; Jason KATZ; Anthony William OPIPARI, Jr.; William R. ROUSH; Hans Martin SEIDEL; Dong-Ming SHEN; Shankar VENKATRAMAN; David Guenther WINKLER
- Web page: https://patentgrep.com/patent/US20220267276A1

## CPC

- C07D 221/16: containing carbocyclic rings other than six-membered
- C07D 221/26: Benzomorphans
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07C 311/60: having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C 335/42: Sulfonylthioureas; Sulfonylisothioureas
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 277/36: Sulfur atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07C 2603/10: containing five-membered rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to treat connected to the modulation of NRLP3.

## Claims

### Claim 1

A compound of Formula AA
wherein
n=0 or 1;
o=1 or 2;
p=0, 1, 2, or 3;
wherein
A is a 5- to 10-membered heteroaryl or a C6-C10 aryl;
B is a 5- to 10-membered heteroaryl or a C6-C10 aryl;
wherein
R1a is a C1-C6 alkyl or —SO2NR11R12;
wherein the C1-C6 alkyl is substituted with one or more hydroxy or —OSi(R13)3; R1b is a C1-C6 alkyl substituted with one or more hydroxy, —SO2NR11R12, —SO2R13, —CONR11R12, —OR11, —COR13; —CO2R13, —NR13CONR11R12; —CR11R12CN, —NR11SO2R13, —NR11CONR11R12, —CR11R12NR11R12, and —NR11COR12;
at least one R6 is ortho to the bond connecting the B ring to the NH(Co) group of Formula AA;
R2 is selected from C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halo, CN, NO2, COC1-C6 alkyl, CO—C6-C10 aryl, CO(5- to 10-membered heteroaryl), CO2C1-C6 alkyl, CO2C3-C8 cycloalkyl, OCOC1-C6 alkyl, OCOC6-C10 and, OCO(5- to 10-membered heteroaryl), OCO(3- to 7-membered heterocycloalkyl), C6-C10 aryl, 5- to 10-membered heteroaryl, NH2, NHC1-C6 alkyl, N(C1-C6 alkyl)2, NHCOC1-C6 alkyl, NHCOC6-C10 aryl, NHCO(5- to 10-membered heteroaryl), NHCO(3- to 7-membered heterocycloalkyl), NHCOC2-C6 alkynyl, NHCOOC1-C6 alkyl, NH—(C=NR13)NR11R12, CONR8R9, SF5, SC1-C6 alkyl, S(O2)C1-C6 alkyl, S(O)C1-C6 alkyl, S(O2)NR11R12, C3-C7 cycloalkyl and 3- to 7-membered heterocycloalkyl, wherein the C1-C6 alkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl and 3- to 7-membered heterocycloalkyl is optionally substituted with one or more substituents each independently selected from hydroxy, halo, CN, oxo, C1-C6 alkyl, C1-C6 alkoxy, COOC1-C6 alkyl, CONR8R9, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), and OCO(3 to 7-membered heterocycloalkyl);
wherein each C1-C6 alkyl substituent and each C1-C6 alkoxy substituent of the R2 C3-C7 cycloalkyl or of the R2 3- to 7-membered heterocycloalkyl is further optionally independently substituted with one to three hydroxy, halo, or oxo;
wherein the 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl of the R2 C1-C6 alkyl, the R2 C1-C6 haloalkyl, the R2 C3-C7 cycloalkyl, or the R2 3- to 7-membered heterocycloalkyl are optionally substituted with one or more substituents independently selected from halo, C1-C6 alkyl, and OC1-C6 alkyl;
R6 and R7 are each independently selected from C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halo, CN, NO2, COC1-C6 alkyl, CO2C1-C6 alkyl, CO2C3-C8 cycloalkyl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(3- to 7-membered heterocycloalkyl), C6-C10 aryl, 5- to 10-membered heteroaryl, NH2, NHC1-C6 alkyl, N(C1-C6 alkyl)2, CONR8R9, SF5, SC1-C6 alkyl, S(O2)C1-C6 alkyl, C5-C10 cycloalkyl and 3- to 10-membered heterocycloalkyl, and C2-C6 alkenyl,
wherein R6 and R7 are each optionally substituted with one or more substituents independently selected from hydroxy, halo, CN, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, ═NR10, COOC1-C6 alkyl, CONR8R9, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(3- to 7-membered heterocycloalkyl), NHCOC1-C6 alkyl, NHCOC6-C10 aryl, NHCO(5- to 10-membered heteroaryl), NHCO(3- to 7-membered heterocycloalkyl), NHCOC2-C6 alkynyl, C6-C10 aryloxy, and S(O2)C1-C6 alkyl; and wherein the C1-C6 alkyl or C1-C6 alkoxy that R6 or R7 is substituted with is optionally substituted with one or more hydroxyl, halo, C6-C10 aryl or NR8R9, or wherein R6 or R7 is optionally fused to a five- to -seven-membered carbocyclic ring or heterocyclic ring containing one or two heteroatoms independently selected from oxygen, sulfur and nitrogen;
wherein the 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, NHCOC6-C10 aryl, NHCO(5- to 10-membered heteroaryl) and NHCO(3- to 7-membered heterocycloalkyl) are optionally substituted with one or more substituents independently selected from halo, C1-C6 alkyl, and OC1-C6 alkyl;
or at least one pair of R6 and R7 on adjacent atoms, taken together with the atoms connecting them, independently form at least one C4-C8 carbocyclic ring or at least one 5- to 8-membered heterocyclic ring containing 1 or 2 heteroatoms independently selected from Q, N, and S, wherein the carbocyclic ring or heterocyclic ring is optionally independently substituted with one or more substituents independently selected from hydroxy, hydroxymethyl, halo, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, CH2NR8R9, ═NR10, COOC1-C6 alkyl, C6-C10 aryl, and CONR8R9;
R10 is C1-C6 alkyl;
each of R8 and R9 at each occurrence is independently selected from hydrogen, C1-C6 alkyl, (C=NR13)NR11R12, S(O)2C1-C6 alkyl, S(O2)NR11R12COR13, CO2R13 and CONR11R12; wherein the C1-C6 alkyl is optionally substituted with one or more hydroxy, halo, C1-C6 alkoxy, C6-C10 and, 5- to 10-membered heteroaryl, C3-C7 cycloalkyl or 3- to 7-membered heterocycloalkyl; or
R8 and R9 taken together with the nitrogen they are attached to form a 3- to 7-membered ring optionally containing one or more heteroatoms in addition to the nitrogen they are attached to;
R13 is C1-C6 alkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl; and
each of R11 and R12 at each occurrence is independently selected from hydrogen and C1-C6 alkyl optionally substituted with hydroxy;
with the proviso that the compound of Formula AA is not a compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 2

A compound of Formula AA
wherein the compound of Formula AA is selected from
wherein
n=0 or 1;
o=1 or 2;
p=0, 1, 2, or 3;
wherein
A′ is a 5- to 10-membered heteroaryl;
B is a 5- to 10-membered heteroaryl or a C6-C10 aryl;
wherein
R1a is a C1-C6 alkyl or —SO2NR11R12;
wherein the C1-C6 alkyl is substituted with one or more hydroxy or —OSi(R13)3;
R1a′ is —SO2NR11R12;
R1a″ is a C1-C6 alkyl;
wherein the C1-C6 alkyl is substituted with one or more hydroxy;
R1a′″ is a C1-C6 alkyl;
wherein the C1-C6 alkyl is substituted with one or more-OSi(R13)3;
R1b is a C1-C6 alkyl substituted with one or more hydroxy, —SO2NR11R12, —SO2R13, —CONR11R12, —OR11, —COR13; —CO2R13, —NR13CONR11R12; —CR11R12CN, —NR11SO2R13, —NR11CONR11R12, —CR11R12NR11R12, and —NR11COR12;
R1b′ is —OR11;
R1b″ is a —SO2NR11R12, —SO2R13, —CONR11R12, —COR13; —CO2R13, —NR13CONR11R12; —CR11R12CN, —NR11SO2R13, —NR11CONR11R12, —CR11R12NR11R12, and —NR11COR12;
R1b′″ is a C1-C6 alkyl substituted with one or more hydroxy;
at least one R5 is ortho to the bond connecting the B ring to the NH(Co) group of Formula AA-1 and Formula AA-4;
at least one R6′ is ortho to the bond connecting the B ring to the NH(CO) group of Formula AA-2;
at least one R6″ is ortho to the bond connecting the B ring to the NH(CO) group of Formula AA-5;
at least one R6′″ is ortho to the bond connecting the B ring to the NH(CO) group of Formula AA-3;
R2 is selected from C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halo, CN, NO2, COC1-C6 alkyl, CO—C6-C10 aryl, CO(5- to 10-membered heteroaryl), CO2C1-C6 alkyl, CO2C3-C8 cycloalkyl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(3- to 7-membered heterocycloalkyl), C6-C10 aryl, 5- to 10-membered heteroaryl, NH2, NHC1-C6 alkyl, N(C1-C6 alkyl)2, NHCOC1-C6 alkyl, NHCOC6-C10 aryl, NHCO(5- to 10-membered heteroaryl), NHCO(3 to 7-membered heterocycloalkyl), NHCOC1-C6 alkynyl, NHCOOC1-C6 alkyl, NH—(C=NR13)NR11R12, CONR8R9, SF5, SC1-C6 alkyl, S(O2)C1-C6 alkyl, S(O)C1-C6 alkyl, S(O2)NR11R12, C3-C7 cycloalkyl, and 3- to 7-membered heterocycloalkyl, wherein the C1-C6 alkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl and 3- to 7-membered heterocycloalkyl is optionally substituted with one or more substituents each independently selected from hydroxy, halo, CN, oxo, C1-C6 alkyl, C1-C6 alkoxy, COOC1-C6 alkyl, CONR8R9, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), and OCO(3- to 7-membered heterocycloalkyl);
wherein each C1-C6 alkyl substituent and each C1-C6 alkoxy substituent of the R2 C3-C7 cycloalkyl or of the R2 3- to 7-membered heterocycloalkyl is further optionally independently substituted with one to three hydroxy, halo, or oxo;
wherein the 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl of the R2 C1-C6 alkyl, the R2 C1-C6 haloalkyl, the R2 C3-C7 cycloalkyl, or the R2 3- to 7-membered heterocycloalkyl are optionally substituted with one or more substituents independently selected from halo, C1-C6 alkyl, and OC1-C6 alkyl;
R6 and R7 are each independently selected from C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halo, CN, NO2, COC1-C6 alkyl, CO2C1-C6 alkyl, CO2C3-C8 cycloalkyl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(3- to 7-membered heterocycloalkyl), C6-C10 aryl, 5- to 10-membered heteroaryl, NH2, NHC1-C6 alkyl, N(C1-C6 alkyl)2, CONR8R9, SF5, SC1-C6 alkyl, S(O2)C1-C6 alkyl, C3-C10 cycloalkyl and 3- to 10-membered heterocycloalkyl, and C2-C6 alkenyl,
wherein R6 and R7 are each optionally substituted with one or more substituents independently-selected from hydroxy, halo, CN, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, ═NR10, COOC1-C6 alkyl, CONR8R9, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(3- to 7-membered heterocycloalkyl), NHCOC1-C6 alkyl, NHCOC6-C10 aryl, NHCO(5- to 10-membered heteroaryl), NHCO(3- to 7-membered heterocycloalkyl), NHCOC2-C0 alkynyl, C6-C10 aryloxy, and S(O2)C1-C6 alkyl, and wherein the C1-C6 alkyl or C1-C6 alkoxy that R6 or R7 is substituted with is optionally substituted with one or more hydroxyl, halo, C6-C10 aryl or NR8R9, or wherein R6 or R7 is optionally fused to a five- to -seven-membered carbocyclic ring or heterocyclic ring containing one or two heteroatoms independently selected from oxygen, sulfur and nitrogen;
wherein the 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, NHCOC6-C10 aryl, NHCO(5- to 10-membered heteroaryl) and NHCO(3- to 7-membered heterocycloalkyl) are optionally substituted with one or more substituents independently selected from halo, C1-C6 alkyl, and OC1-C6 alkyl;
or at least one pair of R6 and R7 on adjacent atoms, taken together with the atoms connecting them, independently form at least one C4-C8 carbocyclic ring or at least one 5- to 8-membered heterocyclic ring containing 1 or 2 heteroatoms independently selected from O, N, and S, wherein the carbocyclic ring or heterocyclic ring is optionally independently substituted with one or more substituents independently selected from hydroxy, hydroxymethyl, halo, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, CH2NR8R9, ═NR10, COOC1-C6 alkyl, C6-C10 aryl, and CONR8R9;
R6′ and R7′ are each independently selected from C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkoxy, C1-C6 haloalkoxy, halo, CN, NO2, COC1-C6 alkyl, CO2C1-C6 alkyl, CO2C3-C8 cycloalkyl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(3- to 7-membered heterocycloalkyl), C6-C10 aryl, 5- to 10-membered heteroaryl, NH2, NHC1-C6 alkyl, N(C1-C6 alkyl)2, CONR8R9, SF5, SC1-C6 alkyl, S(O2)C1-C6 alkyl, C3-C10 cycloalkyl and 3- to 10-membered heterocycloalkyl, and C2-C6 alkenyl,
wherein R6′ and R7′ are each optionally substituted with one or more substituents independently selected from hydroxy, halo, CN, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, ═NR10, COOC1-C6 alkyl, CONR8R9, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(3- to 7-membered heterocycloalkyl), NHCOC1-C6 alkyl, NHCOC1-C6 aryl, NHCO(5- to 10-membered heteroaryl), NHCO(3- to 7-membered heterocycloalkyl), NHCOC2-C6 alkynyl, C6-C10 aryloxy, and S(O2)C1-C6 alkyl; and wherein the C1-C6 alkyl or C1-C6 alkoxy that R6′ or R7′ is substituted with is optionally substituted with one or more hydroxyl, halo, C6-C10 aryl or NR8R9, or wherein R6′ or R7′ is optionally fused to a five- to -seven-membered carbocyclic ring or heterocyclic ring containing one or two heteroatoms independently selected from oxygen, sulfur and nitrogen;
wherein the 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, NHCOC6-C10 aryl, NHCO(5- to 10-membered heteroaryl) and NHCO(3- to 7-membered heterocycloalkyl) are optionally substituted with one or more substituents independently selected from halo, C1-C6 alkyl, and OC1-C6 alkyl,
or at least one pair of R6 and R on adjacent atoms, taken together with the atoms connecting them, independently form at least one C4-C8 carbocyclic ring or at least one 5- to 8-membered heterocyclic ring containing 1 or 2 heteroatoms independently selected from O, N, and S, wherein the carbocyclic ring or heterocyclic ring is optionally independently substituted with one or more substituents independently selected from hydroxy, hydroxymethyl, halo, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, CH2NR8R9, ═NR10, COOC1-C6 alkyl, C6-C10 aryl, and CONR8R9;
R6″ and R7″ are each independently selected from C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, F, Br, I, CN, NO2, COC1-C6 alkyl, CO2C1-C6 alkyl, CO2C3-C8 cycloalkyl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(3- to 7-membered heterocycloalkyl), C6-C10 aryl, 5- to 10-membered heteroaryl, NH2, NHC1-C6 alkyl, N(C1-C6 alkyl)2, CONR8R9, SF5, SC1-C6 alkyl, S(O2)C1-C6 alkyl, C3-C10 cycloalkyl and 3- to 10-membered heterocycloalkyl, and C2-C6 alkenyl,
wherein R6″ and R7″ are each optionally substituted with one or more substituents independently selected from hydroxy, halo, CN, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, ═NR10, COOC1-C6 alkyl, CONR8R9, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(3- to 7-membered heterocycloalkyl), NHCOC1-C6 alkyl, NHCOC6-C10 aryl, NHCO(5- to 10-membered heteroaryl), NHCO(3- to 7-membered heterocycloalkyl), NHCOC2-C6 alkynyl, C6-C10 aryloxy, and S(O2)C1-C6 alkyl; and wherein the C1-C6 alkyl or C1-C6 alkoxy that R6″ or R7″ is substituted with is optionally substituted with one or more hydroxyl, halo, C6-C10 aryl or NR8R9, or wherein R6″ or R7″ is optionally fused to a five- to -seven-membered carbocyclic ring or heterocyclic ring containing one or two heteroatoms independently selected from oxygen, sulfur and nitrogen;
wherein the 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, NHCOC6-C10 aryl, NHCO(5- to 10-membered heteroaryl) and NHCO(3- to 7-membered heterocycloalkyl) are optionally substituted with one or more substituents independently selected from halo, C1-C6 alkyl, and OC1-C6 alkyl,
or at least one pair of R6″ and R7″ on adjacent atoms, taken together with the atoms connecting them, independently form at least one C4-C8 carbocyclic ring or at least one 5- to 8-membered heterocyclic ring containing 1 or 2 heteroatoms independently selected from O, N, and S, wherein the carbocyclic ring or heterocyclic ring is optionally independently substituted with one or more substituents independently selected from hydroxy, hydroxymethyl, halo, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, CH2NR8R9, ═NR10, COOC1-C6 alkyl, C6-C10 aryl, and CONR8R9;
R6′″ and R7′″ are each independently selected from C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, Br, I, CN, NO2, COC1-C6 alkyl, CO2C1-C6 alkyl, CO2C3-C8 cycloalkyl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(3- to 7-membered heterocycloalkyl), C6-C10 aryl, 5- to 10-membered heteroaryl, NH2, NHC1-C6 alkyl, N(C1-C6 alkyl)2, CONR8R9, SF5, SC1-C6 alkyl, S(O2)C1-C6 alkyl, C3-C10 cycloalkyl and 3- to 10-membered heterocycloalkyl, and C2-C0 alkenyl,
wherein R6′″ and R7′″ are each optionally substituted with one or more substituents independently selected from hydroxy, halo, CN, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, ═NR10, COOC1-C6 alkyl, CONR8R9, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(3- to 7-membered heterocycloalkyl), NHCOC1-C6 alkyl, NHCOC6-C10 aryl, NHCO(5- to 10-membered heteroaryl), NHCO(3- to 7-membered heterocycloalkyl), NHCOC2-C6 alkynyl, C6-C10 aryloxy, and S(O2)C1-C6 alkyl; and wherein the C1-C6 alkyl or C1-C6 alkoxy that R6′″ or R7′″ is substituted with is optionally substituted with one or more hydroxyl, halo, C6-C10 aryl or NR8R9, or wherein R6′″ or R7′″ is optionally fused to a five- to -seven-membered carbocyclic ring or heterocyclic ring containing one or two heteroatoms independently selected from oxygen, sulfur and nitrogen;
wherein the 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, NHCOC6-C10 aryl, NHCO(5 to 10-membered heteroaryl) and NHCO(3- to 7-membered heterocycloalkyl) are optionally substituted with one or more substituents independently selected from halo, C1-C6 alkyl, and OC1-C6 alkyl;
or at least one pair of R6′″ and R7′″ on adjacent atoms, taken together with the atoms connecting them, independently form at least one C4, C6, C7, or C8 carbocyclic ring or at least one 5- to 8-membered heterocyclic ring containing 1 or 2 heteroatoms independently selected from O, N, and S, wherein the carbocyclic ring or heterocyclic ring is optionally independently substituted with one or more substituents independently selected from hydroxy, hydroxymethyl, halo, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, CH2NR8R9, ═NR10, COOC1-C6 alkyl, C6-C10 aryl, and CONR8R9;
R10 is C1-C6 alkyl;
each of R8 and R9 at each occurrence is independently selected from hydrogen, C1-C6 alkyl, (C=NR13)NR11R12, S(O)2C1-C6 alkyl, S(O2)NR11R12, COR13, CO2R13 and CONR11R12; wherein the C1-C6 alkyl is optionally substituted with one or more hydroxy, halo, C1-C6 alkoxy, C6-C10 and, 5- to 10-membered heteroaryl, C3-C7 cycloalkyl or 3- to 7-membered heterocycloalkyl; or
R8 and R9 taken together with the nitrogen they are attached to form a 3- to 7-membered ring optionally containing one or more heteroatoms in addition to the nitrogen they are attached to, R13 is C1-C6 alkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl;
each of R11 and R12 at each occurrence is independently selected from hydrogen and C1-C6 alkyl optionally substituted with hydroxy;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 3)

The compound of claim 3, wherein the compound of Formula AA is

### Claim 4 (depends on 3)

The compound of claim 3, wherein the compound of Formula AA is

### Claim 5 (depends on 3)

The compound of claim 3, wherein the compound of Formula AA is

### Claim 6 (depends on 3)

The compound of claim 3, wherein the compound of Formula AA is

### Claim 7 (depends on 3)

The compound of claim 3, wherein the compound of Formula AA is

### Claim 8 (depends on 3)

The compound of claim 3, wherein the compound of Formula AA is

### Claim 9 (depends on 1)

The compound of claim 1, wherein A is a 5- to 6-membered heteroaryl containing 1 sulfur ring member.

### Claim 10 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein A is thiazolyl.

### Claim 11 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein A is oxazolyl.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1-11, wherein n=0.

### Claim 13 (depends on 1, 9)

The compound of any one of claims 1, 9, and optionally 10, wherein the substituted ring A is
or wherein the substituted ring A is
or wherein the substituted ring A is
or wherein the substituted ring A is
wherein the substituted ring A is
or wherein the substituted ring A is

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1-11, wherein n=1.

### Claim 15 (depends on 1)

The compound of any one of claims 1, and 12, wherein the substituted ring A is

### Claim 16 (depends on 1)

The compound of any one of claims 1, and 14, wherein the substituted ring A is
or wherein the substituted ring A is
or wherein the substituted ring A is
or wherein the substituted ring A is

### Claim 17 (depends on 1)

The compound of any one of claims 1, and 12, wherein the substituted ring A is
or wherein the substituted ring A is

### Claim 18 (depends on 1, 2, 3, 13)

The compound of any one of claims 1-3 and 13, wherein the substituted ring A is
or wherein the substituted ring A is

### Claim 19 (depends on 1, 2)

The compound of any one of claims 1-2, and 4, wherein the substituted ring A is
or wherein the substituted ring A is

### Claim 20 (depends on 1, 2, 3, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-3 and 9-16, wherein R1a is C1-C6 alkyl substituted with one or more hydroxy; or
wherein R1a is C1-C6 alkyl substituted with one or more —OSi(R13)3; or
wherein R1a is —SO2NR11R12.

### Claim 21 (depends on 1, 2, 3, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The compound of any one of claims 1-3 and 9-17, wherein R1b is independently selected from the group consisting of C1-C6 alkyl substituted with one or more hydroxy, —SO2NR11R12, —SO2R13, —CONR11R12, —OR11, —COR13; —NR13CONR11R12; —CR11R12CN, —NR11SO2R13, —NR11CONR11R12, and —NR11COR12; or
wherein R1b is independently selected from the group consisting of —SO2NR11R12, —SO2R13, —CONR11R12, —COR13, —CO2R13, —NR13CONR11R12; and —CR11R12CN; or
wherein R1b is —SO2NHMe, SO2NHCH2CH2OH, SO2Me, CONHMe, or OMe; or
wherein R1b is —SO2NHMe or OMe.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10, and 16, wherein R2 is independently selected from the group consisting of hydroxymethyl, C2 alkyl substituted with hydroxy, C3 alkyl substituted with hydroxy, C4 alkyl substituted with hydroxy, C5 alkyl substituted with hydroxy, and C6 alkyl substituted with hydroxy; or
wherein R2 is selected from the group consisting of hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2-hydroxy-2-propyl, 3-hydroxy-2-propyl, 1-hydroxy-1-propyl, 2-hydroxy-1-propyl, 3-hydroxy-1-propyl, 4-hydroxy-1-butyl, 5-hydroxy-1-pentyl, and 6-hydroxy-1-hexyl; or
wherein R2 is selected from the group consisting of hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2-hydroxy-2-propyl, 3-hydroxy-2-propyl, 1-hydroxy-1-propyl, 2-hydroxy-1-propyl, 3-hydroxy-1-propyl, 4-hydroxy-1-butyl, and 6-hydroxy-1-hexyl; or
wherein R2 is selected from the group consisting of C1-C6 alkyl optionally substituted with one or more hydroxy, halo, oxo, or C1-C6 alkoxy, C3-C7 cycloalkyl optionally substituted with one or more hydroxy, halo, oxo, C1-C6 alkoxy, or C1-C6 alkyl wherein the C1-C6 alkoxy or C1-C6 alkyl is further optionally substituted with one to three hydroxy, halo, or oxo; 3- to 7-membered heterocycloalkyl optionally substituted with one or more hydroxy, halo, oxo, or C1-C6 alkyl, wherein the C1-C6 alkoxy or C1-C6 alkyl is further optionally substituted with one to three hydroxy, halo, or oxo, C1-C6 haloalkyl;
C1-C6 alkoxy; C1-C6 haloalkoxy; halo; CN; CO—C1-C6 alkyl; CO—C6-C10 aryl; CO(5- to 10-membered heteroaryl); CO2C1-C6 alkyl, CO2C3-C8 cycloalkyl; OCOC1-C6 alkyl;
OCOC6-C10 aryl; OCO(5- to 10-membered heteroaryl); OCO(3- to 7-membered heterocycloalkyl); C6-C10 aryl; 5- to 10-membered heteroaryl; NH2; NHC1-C6 alkyl;
N(C1-C6 alkyl)2; CONR8R9; SF5; S(O2)NR11R12; S(O)C1-C6 alkyl; and S(O2)C1-C6 alkyl; or
wherein R2 is selected from the group consisting of fluoro; chloro; cyano; methyl;
methoxy; ethoxy; isopropyl; 1-hydroxy-2-methylpropan-2-yl; 2-hydroxy-2-propyl;
hydroxymethyl; 1-hydroxyethyl; 2-hydroxyethyl; l-hydroxy-2-propyl; 1-hydroxy-1-cyclopropyl; COCH3; COPh; 2-methoxy-2-propyl; phenyl; S(O2)CH3; and S(O2)NR11R12.

### Claim 23 (depends on 1, 2, 3, 6, 8)

The compound of any one of claims 1-3, 6, 8, and 9-22, wherein B is phenyl substituted with 1 or 2 R6 and optionally substituted with 1, 2, or 3 R7.

### Claim 24 (depends on 23)

The compound of claim 23, wherein o=2 and p=0.

### Claim 25 (depends on 23, 24)

The compound of any one of claims 23 and 24, wherein the optionally substituted ring B is

### Claim 26 (depends on 25)

The compound of claim 25, wherein each R6 is independently selected from the group consisting of: C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halo, CN, C6-C10 aryl, 5- to 10-membered heteroaryl, CO—C1-C6 alkyl; CONR8R9, and 4- to 6-membered heterocycloalkyl, wherein the C1-C6 alkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl and 4- to 6-membered heterocycloalkyl is optionally substituted with one or more substituents each independently selected from hydroxy, halo, CN, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, ═NR10, COOC1-C6 alkyl, CONR8R9, 4-to 6-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(4- to 6-membered heterocycloalkyl), NHCOC1-C6 alkyl, NHCOC6-C10 and, NHCO(5- to 10-membered heteroaryl), NHCO(4- to 6-membered heterocycloalkyl), and NHCOC2-C6 alkynyl; or wherein each R6 is independently selected from the group consisting of: C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C1-C6 haloalkoxy, wherein the C1-C6 alkyl, C1-C6 haloalkyl, and C3-C7 cycloalkyl is optionally substituted with one or more substituents each independently selected from hydroxy, halo, CN, or oxo.

### Claim 27 (depends on 23)

The compound of claim 23, wherein o=1 and p=1; or
wherein o=2 and p=1.

### Claim 28 (depends on 27)

The compound of claim 27, wherein the optionally substituted ring B is

### Claim 29 (depends on 28)

The compound of claim 28, wherein each R6 is independently selected from C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halo, CN, C6-C10 aryl, 5- to 10-membered heteroaryl, CO—C1-C6 alkyl, CONR8R9, and 4- to 6-membered heterocycloalkyl,
wherein the C1-C6 alkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl and 4- to 6-membered heterocycloalkyl is optionally substituted with one or more substituents each independently selected from hydroxy, halo, CN, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, ═NR10, COOC1-C6 alkyl, CONR8R9, 4- to 6-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(4- to 6-membered heterocycloalkyl), NHCOC1-C6 alkyl, NHCOC6-C10 aryl, NHCO(5- to 10-membered heteroaryl), NHCO(4- to 6-membered heterocycloalkyl), and NHCOC2-C6 alkynyl;
wherein R is independently selected from C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halo, CN, COC1-C6 alkyl, CO2C1-C6 alkyl, CO2C3-C6 cycloalkyl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(3- to 7-membered heterocycloalkyl), C6-C10 aryl, 5- to 10-membered heteroaryl, CONR8R9, SF5, S(O2)C1-C6 alkyl, C3-C7 cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein the C1-C6 alkyl is optionally substituted with one to two C1-C6 alkoxy.

### Claim 30 (depends on 23)

The compound of claim 23, wherein o=2 and p=2.

### Claim 31 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein the optionally substituted ring B is

### Claim 32 (depends on 30, 31)

The compound of any one of claims 30 and 31, wherein each R6 is independently selected from C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halo, CN, C6-C10 aryl, 5- to 10-membered heteroaryl, CO—C1-C6 alkyl, CONR8R9, and 4-to 6-membered heterocycloalkyl,
wherein the C1-C6 alkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl and 4- to 6-membered heterocycloalkyl is optionally substituted with one or more substituents each independently selected from hydroxy, halo, CN, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, ═NR10, COOC1-C6 alkyl, CONR8R9, 4- to 6-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(4- to 6-membered heterocycloalkyl), NHCOC1-C6 alkyl, NHCOC6-C10 aryl, NHCO(5- to 10-membered heteroaryl), NHCO(4- to 6-membered heterocycloalkyl), and NHCOC2-C6 alkynyl;
wherein each R is independently selected from C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halo, CN, COC1-C6 alkyl, C1-C6 alkyl, CO2C3-C6 cycloalkyl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(3- to 7-membered heterocycloalkyl), C6-C10 aryl, 5- to 10-membered heteroaryl, CONR8R9, SF5, S(O2)C1-C6 alkyl, C3-C7 cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein the C1-C6 alkyl is optionally substituted with one to two C1-C6 alkoxy;
or at least one pair of R6 and R7 on adjacent atoms, taken together with the atoms connecting them, independently form at least one C4-C7 carbocyclic ring or at least one 5-to-7-membered heterocyclic ring containing 1 or 2 heteroatoms independently selected from O, N, and S, wherein the carbocyclic ring or heterocyclic ring is optionally independently substituted with one or more substituents independently selected from hydroxy, halo, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, ═NR10, COOC1-C6 alkyl, C6-C10 and, and CONR8R9.

### Claim 33 (depends on 30)

The compound of claim 30, wherein the optionally substituted ring B is

### Claim 34 (depends on 33)

The compound of claim 33, wherein each R6 is independently selected from C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halo, CN, C6-C10 aryl, 5- to 10-membered heteroaryl, CO—C3-C6 alkyl, CONR8R9, and 4- to 6-membered heterocycloalkyl,
wherein the C1-C6 alkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl and 4- to 6-membered heterocycloalkyl is optionally substituted with one or more substituents each independently selected from hydroxy, halo, CN, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, ═NR10, COOC1-C6 alkyl, CONR8R9, 4- to 6-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(4- to 6-membered heterocycloalkyl), NHCOC1-C6 alkyl, NHCOC6-C10 aryl, NHCO(5- to 10-membered heteroaryl), NHCO(4- to 6-membered heterocycloalkyl), and NHCOC2-C6 alkynyl;
wherein each R7 is independently selected from C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halo, CN, COC1-C6 alkyl, CO2C1-C6 alkyl, CO2C3-C6 cycloalkyl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(3- to 7-membered heterocycloalkyl), C6-C10 and, 5- to 10-membered heteroaryl, CONR8R9, SF5, S(O2)C1-C6 alkyl, C3-C7 cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein the C1-C6 alkyl is optionally substituted with one to two C1-C6 alkoxy;
or R6 and R7, taken together with the atoms connecting them, independently form C4-C7 carbocyclic ring or at least one 5-to-7membered heterocyclic ring containing 1 or 2 heteroatoms independently selected from O, N, and S, wherein the carbocyclic ring or heterocyclic ring is optionally independently substituted with one or more substituents independently selected from hydroxy, halo, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, =NR10, COOC1-C6 alkyl, C6-C10 and, and CONR8R9.

### Claim 35 (depends on 23)

The compound of claim 23, wherein o=2 and p=3

### Claim 36 (depends on 35)

The compound of claim 35, wherein the optionally substituted ring B is

### Claim 37 (depends on 36)

The compound of claim 36, wherein the optionally substituted ring B is

### Claim 38 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein the optionally substituted ring B is

### Claim 39 (depends on 36)

The compound of claim 36, wherein each R6 is independently selected from C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halo, CN, C6-C10 aryl, 5- to 10-membered heteroaryl, CO—C1-C6 alkyl, CONR8R9, and 4- to 6-membered heterocycloalkyl,
wherein the C1-C6 alkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl and 4- to 6-membered heterocycloalkyl is optionally substituted with one or more substituents each independently selected from hydroxy, halo, CN, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, ═NR10, COOC1-C6 alkyl, CONR8R9, 4- to 6-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(4 to 6-membered heterocycloalkyl), NHCOC1-C6 alkyl, NHCOC6-C10 aryl, NHCO(5- to 10-membered heteroaryl), NHCO(4- to 6-membered heterocycloalkyl), and NHCOC2-C6 alkynyl;
wherein each R7 is independently selected from C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halo, CN, COC1-C6 alkyl, CO2C1-C6 alkyl, CO2C3-C6 cycloalkyl, OCOC1-C6 alkyl, OCOC6-C10 aryl, OCO(5- to 10-membered heteroaryl), OCO(3- to 7-membered heterocycloalkyl), C6-C10 aryl, 5- to 10-membered heteroaryl, CONR8R9, SF5, S(O2)C1-C6 alkyl, C3-C7 cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein the C1-C6 alkyl is optionally substituted with one to two C1-C6 alkoxy;
or at least one pair of R6 and R on adjacent atoms, taken together with the atoms connecting them, independently form at least one C4-C7 carbocyclic ring or at least one 5-to-7-membered heterocyclic ring containing 1 or 2 heteroatoms independently selected from O, N, and S, wherein the carbocyclic ring or heterocyclic ring is optionally independently substituted with one or more substituents independently selected from hydroxy, halo, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, ═NR10, COOC1-C6 alkyl, C6-C10 aryl, and CONR8R9.

### Claim 40 (depends on 1, 2, 3, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 31)

The compound of any one of claims 1-3, 6, 8-25, 30-31, and 36-37, wherein two pairs of R6 and R7 on adjacent atoms, taken together with the atoms connecting them, independently form at least one C4-C8 carbocyclic ring or at least one 5-to 8-membered heterocyclic ring containing 1 or 2 heteroatoms independently selected from O, N, and S, wherein the carbocyclic ring or heterocyclic ring is optionally independently substituted with one or more substituents independently selected from hydroxy, hydroxymethyl, halo, oxo, C1-C6 alkyl, C1-C6 alkoxy, NR8R9, CH2NR8R9, —NR10, COOC1-C6 alkyl, C6-C10 aryl, and CONR8R9.

### Claim 41 (depends on 1, 2, 3, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 28, 30, 31, 33)

The compound of any one of claims 1-3, 6, 8-25, 27-28, 30, 31, 33, and 36-37, wherein each R6 is independently selected from CN, C1-C6 alkyl, 5- to 10-membered heteroaryl, and 3- to 7-membered heterocycloalkyl;
wherein the C1-C6 alkyl is optionally substituted with one or more substituents each independently selected from hydroxyl or C1-C6 alkoxy; or
wherein each R7 is independently selected from CN, C1-C6 alkyl, 5- to 10-membered heteroaryl, and 3- to 7-membered heterocycloalkyl;
wherein the C1-C6 alkyl is optionally substituted with one or more substituents each independently selected from hydroxyl or C1-C6 alkoxy.

### Claim 42

The compound of any one of the preceding claims, wherein R3 is hydrogen.

### Claim 43

A compound selected from the group consisting of the compound s below:
Compound
Structure
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
and pharmaceutically acceptable salts thereof.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

A pharmaceutical composition comprising a compound or salt as claimed in any one of claims 1-43 and one or more pharmaceutically acceptable excipients.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method for modulating NRLP3 activity, the method comprising contacting NRLP3 with an effective amount of a compound as claimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44.

### Claim 46 (depends on 45)

The method of claim 45, wherein the modulating comprises antagonizing NRLP3.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease, disorder or condition that is a metabolic disorder, comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44,
wherein the metabolic disorder is Type 2 diabetes, atherosclerosis, obesity or gout.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease, disorder or condition that is a disease of the central nervous system, comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44,
wherein the disease of the central nervous system is Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease, disorder or condition that is lung disease, comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44,
wherein the lung disease is asthma, COPD or pulmonary idiopathic fibrosis.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease, disorder or condition that is liver disease, comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44,
wherein the liver disease is NASH syndrome, viral hepatitis or cirrhosis.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease, disorder or condition that is pancreatic disease, comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44,
wherein the pancreatic disease is acute pancreatitis or chronic pancreatitis.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease, disorder or condition that is kidney disease, comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44, wherein the kidney disease is acute kidney injury or chronic kidney injury.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease, disorder or condition that is intestinal disease, comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44, wherein the intestinal disease is Crohn's disease or Ulcerative Colitis.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease, disorder or condition that is skin disease, comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44, wherein the skin disease is psoriasis.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease, disorder or condition that is musculoskeletal disease, comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44, wherein the musculoskeletal disease is scleroderma.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease, disorder or condition that is a vessel disorder, comprising administering to a subject in need of such treatment an effective amount of a compound as cl aimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44, wherein the vessel disorder is giant cell arteritis.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease, disorder or condition that is a disorder of the bones, comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44, wherein the disorder of the bones is osteoarthritis, osteoporosis or osteopetrosis disorders.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease, disorder or condition that is eye disease, comprising administering to a subject in need of such treatment an effective amount of a compound as cl aimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44, wherein the eye disease is glaucoma or macular degeneration.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease, disorder or condition that is a disease caused by viral infection, comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44, wherein the diseases caused by viral infection is HIV or AIDS.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease, disorder or condition that is an autoimmune disease, comprising administering to a subject in need of such treatment an effective amount of a compound as cl aimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44, wherein the autoimmune disease is Rheumatoid Arthritis, Systemic Lupus Erythematosus, Autoimmune Thyroiditis.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease, disorder or condition that is cancer or aging, comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease, disorder or condition that is a cancer selected from: myeiodysplastic syndromes (AIDS): non-small cell lung cancer, such as non-small cell lung cancer in patients carrying mutation or overexpression of NLRP3; acute lymphoblastic leukemia (ALL), such as ALL in patients resistant to glucocorticoids treatment; Langerhan's cell histiocytosis (LCH); multiple myeloma; promyelocytic leukemia; acute myeloid leukemia (AML) chronic myeloid leukemia (CML); gastric cancer; and lung cancer metastasis, comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of claims 1-43 or a pharmaceutical composition as claimed in claim 44.

### Claim 63 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method of any one of claims 47-62, further comprising administering a therapeutically effective amount of an anti-TNFα agent to the subject.
